Does isoniazid chemoprophylaxis increase the frequency of hepatotoxicity in patients receiving anti-TNF-alpha agent with a disease-modifying antirheumatic drug?

ÜSKÜDAR CANSU, DÖNDÜ; Guncan, Sabri; Bilge, NAZİFE; KAŞİFOĞLU, TİMUÇİN; KORKMAZ, CENGİZ

doi:10.5152/eurjrheumatol.2014.019

Does isoniazid chemoprophylaxis increase the frequency of hepatotoxicity in patients receiving anti-TNF-alpha agent with a disease-modifying antirheumatic drug?

ÜSKÜDAR CANSU D., Guncan S., Bilge N. Ş., KAŞİFOĞLU T., KORKMAZ C.

EUROPEAN JOURNAL OF RHEUMATOLOGY, cilt.1, sa.2, ss.62-66, 2014 (ESCI)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 1 Sayı: 2
Basım Tarihi: 2014
Doi Numarası: 10.5152/eurjrheumatol.2014.019
Dergi Adı: EUROPEAN JOURNAL OF RHEUMATOLOGY
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.62-66
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Objective: The aim of this study is to determine the incidence of isoniazid (INH)-related hepatotoxicity in patients with rheumatologic diseases receiving tumor necrosis factor-alpha (TNF-alpha) antagonists along with a disease-modifying antirheumatic drug (DMARD).